Ms. Mira Dhyana Wonderwheel Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 19375 Hwy 116, Monte Rio, CA 95462 Phone: 707-865-1200 |
Dina Vineberg Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 22664 Sylvan Way, Monte Rio, CA 95462 Phone: 707-210-8445 |
Ms. Denise Emily Horner Counselor - Mental Health Medicare: Medicare Enrolled Practice Location: 19375 Highway 116, Monte Rio, CA 95462 Phone: 707-865-1200 Fax: 707-865-3151 |
Alannah Judith Tomich Counselor Medicare: Not Enrolled in Medicare Practice Location: 20025 El Rancho Way, Monte Rio, CA 95462 Phone: 865-789-5680 |
Diana B Holloway, MFT Counselor Medicare: Medicare Enrolled Practice Location: 19375 Hwy 116, Monte Rio, CA 95462 Phone: 707-865-1200 |
Chauntel Wiggins, M.A. Counselor - Mental Health Medicare: Medicare Enrolled Practice Location: 19375 California 116, Monte Rio, CA 95462 Phone: 707-865-1200 |
Lynn Marie Gordon, PH.D. Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 19375 Highway 116, Monte Rio, CA 95462 Phone: 707-865-1200 Fax: 707-865-3151 |
Ms. Janet De Wald Counselor Medicare: Not Enrolled in Medicare Practice Location: 19375 Highway 116, Monte Rio, CA 95462 Phone: 707-865-1200 |
Ms. Heather Darlene Litke, L.P.C.C. Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 19100 Church St, Monte Rio, CA 95462 Phone: 925-708-0278 |
News Archive
People with inflammatory bowel disease may also be at risk for developing nerve damage and other neurological problems, according to research that will be presented at the American Academy of Neurology's 59th Annual Meeting in Boston, April 28 , May 5, 2007.
Twenty-four month findings from IMPROVE HF, (The Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting), funded by Medtronic, Inc., demonstrated that clinics using the process improvement program increased adherence to evidence-based, guideline-recommended care by 82 and 62 percent, respectively, for cardiac resynchronization therapy (CRT) and implantable cardioverter-defibrillator (ICD) use, and 80 percent for aldosterone antagonist use, all relative to baseline results.
Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the Biologic License Applications (BLA) for Prolia(TM) (denosumab) in the treatment and prevention of postmenopausal osteoporosis.
Landauer, Inc., a recognized leader in personal and environmental radiation measurement and monitoring, outsourced medical physics services and high quality medical consumable accessories, today reported financial results for its fiscal 2013 first quarter ended December 31, 2012.
› Verified 8 days ago